Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD20 CAR T cells LUCAR-20SP

A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20SP specifically recognize and kill CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.
Synonym:allogeneic anti-CD20 CAR-T cells LUCAR-20SP
Code name:LUCAR 20SP
LUCAR-20SP
LUCAR20SP
Search NCI's Drug Dictionary